Abstract: Bullous pemphigoid （BP） is a common autoimmune subepidermal bullous skin disease that predominantly affects the elderly with a high recurrence rate and mortality. In recent years, the emergence of biological agents, complement inhibitors and Janus kinase (JAK) inhibitors targeting different targets has provided more therapeutic options for BP. This paper reviews the new treatments for BP to provide reference for clinical application.

Key words: bullous pemphigoid, biological agents, JAK inhibitors